Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Baricitinib can lead to hair regrowth in alopecia areata but may also cause relapses.

This review discusses the role of the JAK/STAT pathway in managing alopecia areata and emphasizes the need for further research to determine the ideal JAK inhibitor, as it reports no new clinical results.

This study found that in-person photobiomodulation treatments improved hair growth in men and some women with androgenetic alopecia, except for the laser band and combination laser/LED helmet in women.

Baricitinib helps with early hair regrowth in people with alopecia areata.

This report describes a rare case of kerion in a 6-year-old boy in Ireland, treated with oral Itraconazole and steroids, highlighting the condition's unusual occurrence in the region.

Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.

This study found that baricitinib improved symptoms of atopic dermatitis and alopecia areata in both adults and children in real-world settings, aligning with clinical trial results, while noting low discontinuation due to adverse events and no new safety concerns.

This study found that ILK deficiency disrupts hair follicle development by impairing cell polarity and laminin-511 assembly, but these defects can be partially reversed with exogenous laminin-511.

This study reports that a robotic and AI-based system successfully analyzes FUE hair transplant procedures, aiding surgeons in planning and assessing operation success through detailed pre-op and post-op evaluations.

This study demonstrated that a 1-step, peroxidase-labeled conjugated antibody method provides more accurate immunoreactivity patterns in hair follicle substructures compared to the 2-step LSAB method, which may cause false-positive staining in sebaceous glands.

This study found that Ishige sinicola ethanol extract and its butanol fraction can protect against lipopolysaccharide-induced muscle atrophy in C2C12 myotubes through antioxidant and anti-inflammatory activities.

This study found that Baricitinib significantly reduced hair loss and immune response in a mouse model of alopecia areata.

This study found that bikunin is expressed in human keratinocytes and may play a role in regulating keratinocyte function during mitosis or inflammation.

Baricitinib effectively promotes beard regrowth in most men with alopecia areata universalis.

This case report highlights the successful treatment of alopecia areata universalis with Baricitinib, suggesting potential long-term effectiveness of janus kinase inhibitors for this autoimmune hair loss condition.

This study observed that baricitinib led to significant hair regrowth and improved psychological well-being in severe alopecia areata patients over 48 weeks, with 63.2% achieving a SALT score of ≤20.

In this open-label study of post-menopausal women with frontal fibrosing alopecia, researchers found that 12 weeks of baricitinib monotherapy significantly reduced disease activity as measured by the Lichen Planopilaris Activity Index, improved patient-reported scalp hair growth, but showed no significant change in eyebrow growth.

In this research, the authors reported that long-term treatment with the JAK1/JAK2 inhibitor baricitinib effectively maintains hair regrowth in patients with severe alopecia areata and may gradually improve outcomes for partial responders over 104 weeks, without increasing side effect incidence.

This paper reports insights from an Expert Panel convened by the Society for Immunotherapy of Cancer on managing immune-related adverse events (irAEs) following immune checkpoint inhibitor therapy, highlighting surveillance gaps and the need for a comprehensive irAE registry to improve post-treatment care for cancer survivors.

This review details how baricitinib successfully demonstrated significant hair regrowth in clinical trials for severe alopecia areata, now leading to its approval as the first systemic therapy for the condition, while also highlighting the importance of assessing individual risk factors for adverse events.

In this study, researchers examined Baricitinib's role as a treatment for Alopecia Areata, contrasting it with conventional therapies, and found that while effective, Baricitinib may cause adverse reactions depending on individual patient health histories.

This review discusses baricitinib's applications for various inflammatory disorders and highlights its promising efficacy alongside potential adverse effects, advocating for further research before it becomes a standard treatment.

This study found that baricitinib significantly reduced alopecia severity in JAK inhibitor-naïve patients compared to those previously treated with tofacitinib, indicating that switching JAK inhibitors can be safe and may be beneficial for selected patients with partial prior responses.

In this study, withdrawal of baricitinib therapy in patients with severe alopecia areata who had achieved hair regrowth led to a loss of benefit in almost all patients, suggesting that continued treatment is necessary to maintain hair regrowth.

This study reviewed therapies for alopecia areata and suggests that Janus kinase inhibitors, such as baricitinib and upadacitinib, show promise in treating both alopecia areata and associated immune-mediated inflammatory diseases.

Isoginkgetin reduces inflammation in cells by blocking NF-κB activation.

This study identified a mutant in Arabidopsis with shorter root hairs due to early growth cessation, implicating the IRE gene in regulating root hair growth duration.

This study found that hypaphorine alters cytoskeletal organization in Eucalyptus globulus root hairs, contributing to reduced root hair elongation by possibly disrupting vesicle delivery needed for growth.